公开(公告)号：US20210177898A1

公开(公告)日：2021-06-17

申请号：US17025607

申请日：2020-09-18

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Kevin R. WEBSTER ,  Rajesh SHARMA ,  Gary CHIANG

IPC: A61K35/17 ,  C07K14/74 ,  A61P35/00 ,  C07K14/725 ,  C07K14/73 ,  C07K14/16 ,  C07K14/705 ,  C12N5/0783 ,  C07D471/04 ,  C07D487/04 ,  C07D495/20 ,  C07D491/20 ,  C07D471/20 ,  A61K31/501

Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.

公开(公告)号：US20230381232A1

公开(公告)日：2023-11-30

申请号：US18158770

申请日：2023-01-24

Applicant: eFFECTOR Therapeutics Inc.

Inventor： Kevin R. WEBSTER ,  Rajesh SHARMA ,  Gary CHIANG

IPC: A61K35/17 ,  C07K14/74 ,  A61P35/00 ,  C07K14/725 ,  C07K14/73 ,  C07K14/16 ,  C07K14/705 ,  C12N5/0783 ,  C07D471/04 ,  C07D487/04 ,  C07D495/20 ,  C07D491/20 ,  C07D471/20 ,  A61K31/501

CPC classification number: A61K35/17 ,  C07K14/70539 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/162 ,  C07K14/70517 ,  C07K14/70589 ,  C07K14/70564 ,  C12N5/0638 ,  C07D471/04 ,  C07D487/04 ,  C07D495/20 ,  C12N5/0636 ,  C07D491/20 ,  C07D471/20 ,  A61K31/501 ,  A61K45/06

Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.

公开(公告)号：US20180353545A1

公开(公告)日：2018-12-13

申请号：US15989098

申请日：2018-05-24

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Kevin R. WEBSTER ,  Rajesh SHARMA ,  Gary CHIANG

IPC: A61K35/17 ,  C07K14/74 ,  A61P35/00 ,  C07K14/725 ,  C07K14/705 ,  C07K14/73 ,  C07K14/16

Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.